Under construction – not a live service
Sign in
CompletedNo phase

Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease

Key facts

Who runs it
University of Leipzig
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
414 people enrolled
Started
Oct 2015
Ended
Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ranger Drug Eluting Balloon
  • In Pact Drug Eluting Balloon
Record updated
20 December 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Subject age ≥ 18
  • Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing Rutherford category 2-4
  • Subject has a de novo or restenotic lesion with ≥ 70% stenosis documented angiographically and no prior stent in the target lesion
  • Target lesion length is ≤ 30cm
  • Target lesion is at least 1cm below the origin of the profunda femoris and does not exceed the medial femoral epicondyle
  • Multiple lesions with max. 3cm healthy vessel segment in between lesions can be considered at the discretion of the operator as one lesion. Total lesion length should not exceed 30 cm
  • Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual estimation
  • Patency of at least one (1) infrapopliteal artery to the ankle (< 50% diameter stenosis) in continuity with the native femoropopliteal artery
  • A guidewire has successfully traversed the target treatment segment

Who cannot take part

  • Prior vascular surgery of the target lesion
  • Stroke or heart attack within 3 months prior to enrollment
  • Any surgical procedure or intervention performed within 30 days prior to or post index procedure
  • Target lesion requires treatment with alternative therapies such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices
  • Enrolled in another investigational drug, device or biologic study
  • Known allergies or sensitivity to heparin, aspirin, other anticoagulant/ antiplatelet therapies, paclitaxel or contrast media that cannot be adequately pre-treated prior to index procedure
  • Failure to successfully cross the target lesion
  • Superficial femoropopliteal Artery or Proximal popliteal artery disease in the opposite leg that requires treatment at the index procedure
  • Angiographic evidence of severe calcification
  • Presence of fresh thrombus in the lesion
  • Presence of aneurysm in the target vessel/s
  • Presence of a stent in the target lesion
  • Life expectancy of less than one year
  • Rutherford classification of 0, 1, 5 or 6

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare two different Paclitaxel coated balloons in the treatment of high grade stenotic or occluded lesions in Superficial femoropopliteal artery (SFA )and/or Proximal Popliteal Artery in Peripheral Artery Disease (PAD) patients with Rutherford class 2-4.

The 2 groups in the trial

  • Ranger Drug Eluting BalloonExisting treatment, for comparison

    Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance

  • In Pact Drug Eluting BalloonExisting treatment, for comparison

    Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective, Randomized, Multi-Center Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease With the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)
Record updated
20 December 2023